Wall Street Zen upgraded shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a hold rating to a buy rating in a research report report published on Saturday morning,Wall Street Zen reports.
A number of other research analysts have also issued reports on the stock. Zacks Research upgraded shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. HC Wainwright reissued a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research report on Tuesday, September 1st. Weiss Ratings upgraded shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, B. Riley Financial raised their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $63.00.
Check Out Our Latest Research Report on TGTX
TG Therapeutics Stock Down 2.7%
Shares of TG Therapeutics stock opened at $62.76 on Friday. TG Therapeutics has a 12-month low of $26.76 and a 12-month high of $68.03. The company has a quick ratio of 3.72, a current ratio of 4.50 and a debt-to-equity ratio of 1.30. The stock has a 50 day moving average price of $56.83 and a two-hundred day moving average price of $45.49. The stock has a market capitalization of $9.49 billion, a P/E ratio of 95.09, a PEG ratio of 5.08 and a beta of 1.89.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). TG Therapeutics had a net margin of 11.81% and a return on equity of 18.82%. The firm had revenue of $259.94 million during the quarter, compared to the consensus estimate of $245.47 million. During the same period in the prior year, the business earned $2.43 EPS. The company’s revenue for the quarter was up 60.8% compared to the same quarter last year. Equities analysts expect that TG Therapeutics will post 1.10 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director Laurence Charney sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the sale, the director owned 168,640 shares of the company’s stock, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.87% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TGTX. Morse Asset Management Inc acquired a new stake in TG Therapeutics during the third quarter valued at approximately $29,000. Farther Finance Advisors LLC raised its holdings in shares of TG Therapeutics by 45.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 312 shares in the last quarter. Bogart Wealth LLC acquired a new position in shares of TG Therapeutics in the 3rd quarter worth approximately $56,000. Jacobi Capital Management LLC acquired a new position in shares of TG Therapeutics in the 3rd quarter worth approximately $57,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 365 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
Further Reading
- Five stocks we like better than TG Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
